



US008648106B2

(12) **United States Patent**
Roychowdhury et al.

(10) **Patent No.:** **US 8,648,106 B2**
(45) **Date of Patent:** ***Feb. 11, 2014**

(54) **DEXMEDETOMIDINE PREMIX
FORMULATION**

(71) Applicant: **Hospira, Inc.**, Lake Forest, IL (US)

(72) Inventors: **Priyanka Roychowdhury**, Foster City,
CA (US); **Robert A. Cedergren**,
Libertyville, IL (US)

(73) Assignee: **Hospira, Inc.**, Lake Forest, IL (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **13/867,861**

(22) Filed: **Apr. 22, 2013**

(65) **Prior Publication Data**

US 2013/0237576 A1 Sep. 12, 2013

Related U.S. Application Data

(63) Continuation of application No. 13/678,260, filed on
Nov. 15, 2012, now Pat. No. 8,436,033, which is a
continuation of application No. 13/541,524, filed on
Jul. 3, 2012, now Pat. No. 8,338,470, which is a
continuation of application No. 13/343,672, filed on
Jan. 4, 2012, now Pat. No. 8,242,158.

(51) **Int. Cl.**
A61K 31/164 (2006.01)
C07D 233/56 (2006.01)

(52) **U.S. Cl.**
USPC **514/396**; 514/816; 548/346.1

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,910,214	A	3/1990	Karjalainen et al.
5,344,840	A	9/1994	Maze et al.
5,716,988	A	2/1998	Ibrahim et al.
6,716,867	B1	4/2004	Aantaa et al.
6,806,291	B1	10/2004	Sunkel et al.
8,242,158	B1	8/2012	Roychowdhury et al.
8,338,470	B1	12/2012	Roychowdhury et al.
8,436,033	B1	5/2013	Roychowdhury et al.
8,455,527	B1	6/2013	Roychowdhury et al.
2010/0094219	A1	4/2010	Kriesel et al.
2010/0197694	A1	8/2010	Horn
2010/0305160	A1	12/2010	Brummett
2010/0326868	A1	12/2010	McClain et al.
2011/0152271	A1	6/2011	Horn
2011/0230534	A1	9/2011	Miyawaki et al.
2011/0269666	A1	11/2011	Quintin

FOREIGN PATENT DOCUMENTS

WO WO 2010/031819 3/2010

OTHER PUBLICATIONS

U.S. Appl. No. 13/343,672, filed Jan. 4, 2012.
U.S. Appl. No. 13/541,524, filed Jul. 3, 2012.
U.S. Appl. No. 13/678,148, filed Nov. 15, 2012.
U.S. Appl. No. 13/678,260, filed Nov. 15, 2012.
U.S. Appl. No. 13/343,672, Jul. 18, 2012 Issue Fee payment.
U.S. Appl. No. 13/343,672, Apr. 18, 2012 Notice of Allowance.
U.S. Appl. No. 13/343,672, Mar. 13, 2012 Response to Non-Final
Office Action (Accelerated Exam).
U.S. Appl. No. 13/343,672, Feb. 13, 2012 Non-Final Office Action.
U.S. Appl. No. 13/541,524, Nov. 20, 2012 Issue Fee payment.
U.S. Appl. No. 13/541,524, Oct. 22, 2012 Notice of Allowance.
U.S. Appl. No. 13/541,524, Sep. 17, 2012 Response to Non-Final
Office Action and Terminal Disclaimer filed.
U.S. Appl. No. 13/541,524, Aug. 17, 2012 Non-Final Office Action.
U.S. Appl. No. 13/678,148, May 9, 2013 Issue Fee payment.
U.S. Appl. No. 13/678,148, Jan. 11, 2013 Notice of Allowance.
U.S. Appl. No. 13/678,260, Apr. 8, 2013 Issue Fee payment.
U.S. Appl. No. 13/678,260, Jan. 8, 2013 Notice of Allowance
“Dexmedetomidine HCL Draft Labeling: Precedex™
Dexmedetomidine Hydrochloride Injection,” FDA approved label,
dated Dec. 17, 1999, and available online Jul. 26, 2001, pp. 1-13.
Downloaded from <http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-038_Precedex_pntlbl.pdf> on Jan. 4, 2012.
FDA Memorandum from Cynthia G. McCormick, M.D., Director,
Division of Anesthetics, Critical Care and Addiction Drug Products,
dated Nov. 30, 1999, in connection with the Medical Reviews of the
Precedex (dexmedetomidine hydrochloride injection) Application
No. 21-038 submitted to the FDA by Abbott Laboratories on Dec. 18,
1998, and available on the FDA website Jul. 26, 2001. Downloaded
on Mar. 7, 2012 from <http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-038_Precedex.dfm>.
Petersen, “Trends in Pharmaceutical Primary Packaging for
Injectables—Solutions for New Challenges,” *Drug Development and
Delivery*, Issue Date: Sep. 2012, Posted on: Sep. 5, 2012. Down-
loaded on Sep. 14, 2012 from <<http://www.drug-dev.com/ME2/dirmod.asp?mod=Publications%3A%3AArticle&mid=8F3A7027421841978F18BE895F87F791&tier=4&id=C2347A2CEAE1422DAA7E592E47648D77>>.
Precedex® Package Insert, Document EN-2680, Hospira, Inc., Sep.
2010, downloaded on Aug. 10, 2012 from <[URL:http://www.precedex.com/wp-content/uploads/2010/11/Precedex_PI.pdf](http://www.precedex.com/wp-content/uploads/2010/11/Precedex_PI.pdf)>, pp.
1-24.

(Continued)

Primary Examiner — Savitha Rao

Assistant Examiner — Gregg Polansky

(74) *Attorney, Agent, or Firm* — Baker Botts LLP

(57) **ABSTRACT**

The presently disclosed subject matter relates to pharmaceu-
tical compositions comprising dexmedetomidine or a phar-
maceutically acceptable salt thereof wherein the composition
is formulated as a liquid for parenteral administration to a
subject, and wherein the composition is disposed within a
sealed container as a premixture. The pharmaceutical com-
positions can be used, for example, in perioperative care of a
patient or for sedation.

9 Claims, No Drawings